drug · antibody
bevacizumab biosimilar
pre_registrationupdated 5mo agoby Shanghai Henlius Biotech Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 20 approved and 146 investigational indications.
indications
indications
NSCLC
targets
Vascular endothelial growth factor A, long form
all catalysts(0)
nothing on the calendar yet
Trials studying bevacizumab biosimilar
- phase3A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- phase3Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- phase2A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
- phase2A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
- phase2A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
- phase1Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
- —Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- phase2ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
News(8)
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 6d ago
- Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugsRoche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.fiercebiotech · 10d ago
- Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…fiercebiotech · 1mo ago
- TME holds onto $1B dream for brain cancer drug as search for partners nears conclusionTME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings to its hope of generating $1 billion in peak sales from the asset.fiercebiotech · 1mo ago
- Vaderis hauls in $152M to test an AKT-targeting drugThe startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.biopharma_dive · 1mo ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 2mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 4mo ago
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 5mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that